MENU

Fox Chase Cancer Center News

November 25, 2020

Fox Chase Researchers Use New CRISPR Library Screening Method to Identify Drug Response, Resistance Mechanisms in Hodgkin Lymphoma Models

PHILADELPHIA (November 25, 2020)—In a recent study, researchers at Fox Chase Cancer Center used a new screening method to identify a previously unrecognized mechanism for resistance and responsiveness in Hodgkin lymphoma models being treated with brentuximab vedotin, also known by its brand name, Adcetris.

November 25, 2020

Five Fox Chase Cancer Center Physicians Named Top Docs 2020 by Main Line Today

PHILADELPHIA (November 25, 2020)— Five Fox Chase Cancer Center physicians have been named as 2020 Top Docs by Main Line Today. Top Docs were selected by regional physicians from a variety of practices, and the physicians from Fox Chase who were honored cover a range of oncologic specialties.

November 19, 2020

New Link Found Between Genetic Variant, Sexually Transmitted Infections, and Prostate Cancer Risk

PHILADELPHIA (November 19, 2020) – Sexually transmitted infections (STIs) have been linked to increased risk for several types of cancer, including prostate cancer. New research out of Fox Chase Cancer Center has shown that a history of STIs combined with a certain single-nucleotide polymorphism (SNP) associated with inflammation decreased risk for prostate cancer among a small group of Jamaican men.

November 17, 2020

Fox Chase Researcher Leads Study on Impact of Funding for American Head and Neck Society

PHILADELPHIA (November 17, 2020)—Results from a recently published study spearheaded by a Fox Chase Cancer Center researcher found that over the last 20 years, research funding provided by the American Head and Neck Society (AHNS) has generated considerable return on investment and achieved the society’s aims of furthering the trajectories of early career researchers.

November 17, 2020

Fox Chase Offering First CAR T Therapy Approved for Mantle Cell Lymphoma

PHILADELPHIA (November 17, 2020)—Patients with mantle cell lymphoma treated at Fox Chase Cancer Center will now have access to treatment with brexucabtagene autoleucel, also known as Tecartus, the first cell-based gene therapy approved by the Food and Drug Administration (FDA).

November 16, 2020

New Edition of Leading Virology Textbook Co-Authored by Two Fox Chase Researchers

PHILADELPHIA (November 16, 2020)—Two leading researchers from Fox Chase Cancer Center are co-authors of the fifth edition of Principles of Virology, the leading virology textbook for undergraduate and graduate students studying how viruses reproduce and cause disease.

November 13, 2020

Researchers Home in on Possible Combination Targets to Treat T-Acute Leukemia/Lymphoma

PHILADELPHIA (November 13, 2020) – In a recently published paper, researchers at Fox Chase Cancer Center unveiled data that suggested possible new targets for the treatment of T-acute leukemia/lymphoma (T-ALL).

November 5, 2020

Gene Editing Technology Harnessed to Identify New, Druggable Targets in Kidney Cancer

PHILADELPHIA (November 5, 2020) – Researchers at Fox Chase Cancer Center have harnessed the power of the Nobel Prize-winning CRISPR/Cas9 technology to identify cellular factors involved in resistance to sunitinib by clear cell renal cell carcinoma.

Pages

Connect with Fox Chase